Markets

Flex Pharma (FLKS) in Focus; Stock Tumbles 8.9%

A generic image of a pen and on top of a chart.
Credit: Shutterstock photo

Flex Pharma, Inc. ( FLKS ) saw a big move last session, as the company's shares fell by nearly 9% on Friday. The move came on pretty good volume too with far more shares changing hands than in a normal session. This reverses the recent trend for FLKS as the stock is now up over 27% since Sep 4.

The biotechnology company has seen a flat track record when it comes to current year estimate revisions over the past few weeks and the consensus for earnings hasn't been in a trend either. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future, and especially on earnings estimates following the recent slump.

FLKS currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.

Investors interested in the Medical-Biomedical/Generic industry may consider better-ranked stock like Gilead Sciences Inc. ( GILD ), which carries a Zacks Rank #1 (Strong Buy).

Is FLKS going up? Or down? Predict to see what others think: Up or Down

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

FLEX PHARMA INC (FLKS): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

SLRX GILD

Other Topics

Investing Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More